OpenCitationsmetadata only

Rituximab Chimeric anti-CD20 Monoclonal Antibody Therapy For Relapsed Indolent Lymphoma: Half Of Patients Respond To A Four-Dose Treatment Program.

McLaughlin, P [omid:ra/061808009298]; Grillo-López, A J [omid:ra/061808009299]; Link, Brian K. [orcid:0000-0001-5084-0698 omid:ra/0613010803182]; Levy, R [omid:ra/061808009300]; Czuczman, M S [omid:ra/061808009301]; Williams, M E [omid:ra/061808009302]; Heyman, M R [omid:ra/061808009303]; Bence-Bruckler, I [omid:ra/061808009304]; White, C A [omid:ra/061808009305]; Cabanillas, F [omid:ra/061808009306]; Jain, V [omid:ra/061808009307]; Ho, A D [omid:ra/061808009308]; Lister, J [omid:ra/061808009309]; Wey, K [omid:ra/061808009310]; Shen, D [omid:ra/061808009311]; Dallaire, B K [omid:ra/061808009312]

OpenCitations · Papers · License: Open Access

Open Source ↗

citations, doi, seed:10.1186/1756-8722-6

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Rituximab Chimeric anti-CD20 Monoclonal Antibody Therapy For Relapsed Indolent Lymphoma: Half Of Patients Respond To A Four-Dose Treatment Program.

Related documents